Related Experiment Video
Updated: Jul 9, 2026
Extracellular Vesicle Tissue Factor Activity Assay
Published on: December 29, 2023
[Plasma concentrations of vascular endothelial growth factor and tissue factor in children with acute lymphoblastic
Hua-Qiang Yang1, Rong-Huan Zhang, Zheng-Hua Zhang
1Department of Hemotology, Taihe Hospital, Yunyang Medical College, Shiyan, Hubei, China. yanghuaqiang2004@126.com
Insights
Plasma concentrations of vascular endothelial cell growth factor (VEGF) and tissue factor (TF) are elevated in children with acute lymphoblastic leukemia (ALL). These markers may help evaluate ALL severity and treatment outcomes.
Area of Science:
- Oncology
- Hematology
- Biochemistry
Context:
- Acute lymphoblastic leukemia (ALL) is a significant pediatric malignancy.
- Understanding the molecular mechanisms and biomarkers in ALL is crucial for improved patient outcomes.
- Vascular endothelial cell growth factor (VEGF) and tissue factor (TF) are implicated in various cancers.
Purpose:
- To quantify plasma levels of VEGF and TF in pediatric ALL patients.
- To investigate the clinical significance of VEGF and TF in relation to ALL risk stratification and treatment response.
- To explore the correlation between VEGF and TF concentrations in ALL.
Summary:
- Plasma VEGF and TF levels were significantly higher in ALL patients compared to healthy controls.
- Elevated VEGF and TF concentrations were observed in non-remission and high-risk ALL groups, both before and after treatment.
- A positive linear correlation was found between plasma VEGF and TF levels in ALL patients prior to treatment.
Impact:
- VEGF and TF may serve as valuable biomarkers for assessing ALL severity and predicting treatment outcomes.
- These findings contribute to the understanding of the role of VEGF and TF in ALL pathogenesis.
- Potential for targeted therapies aimed at VEGF and TF pathways in ALL management.
Objective:
To detect plasma concentrations of vascular endothelial cell growth factor (VEGF) and tissue factor (TF) in children with acute lymphoblastic leukemia (ALL) and explore their clinical significance in ALL.
Methods:
Thirty-three children with newly diagnosed ALL, including 18 cases of low risk, 7 cases of moderate risk and 8 cases of high risk, were enrolled in this study. Twenty-five patients received a complete remission and 8 cases were in non-remission after conventional remission induction chemotherapy. Plasma concentrations of VEGF and TF in the patients were detected using ELISA before and after treatment. Sixteen healthy children served as normal control group.
Results:
Plasma concentrations of VEGF and TF in ALL patients before treatment were significantly higher than those in normal controls (P < 0.01). Plasma concentrations of VEGF and TF in the non-remission group before treatment were significantly higher than those in the remission group (P < 0.05) and the control group (P < 0.01). After treatment the plasma concentrations of VEGF and TF in the non-remission group were not significantly reduced and higher than those in the remission and the control groups (P < 0.01). There were significant differences in plasma concentrations of VEGF and TF among the low-risk, moderate-risk and high-risk groups before and after treatment (P < 0.05). Plasma concentrations of VEGF and TF in the high risk group were not significantly reduced after treatment and higher than those in the control group (P < 0.01). A linear correlation was noted between plasma VEGF and TF concentrations in ALL patients before treatment (r=0.50, P < 0.01).
Conclusions:
VEGF and TF play an important role in the development of ALL and may be useful to the evaluation of the severity and the outcome in ALL.
Related Concept Videos
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
01:24Regulation of Angiogenesis and Blood Supply
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution